Improving the limit of detection for Sanger sequencing: A comparison of methodologies for KRAS variant detection.

Fluorescent dye terminator Sanger sequencing (FTSS), with detection by automated capillary electrophoresis (CE), has long been regarded as the gold standard for variant detection. However, software analysis and base-calling algorithms used to detect mutations were largely optimized for resequencing applications in which different alleles were expected as heterozygous mixtures of 50%. Increasingly, the requirements for variant detection are an analytic sensitivity for minor alleles of <20%, in particular, when assessing the mutational status of heterogeneous tumor samples. Here, we describe a simple modification to the FTSS workflow that improves the limit of detection of cell-line gDNA mixtures from 50%-20% to 5% for G>A transitions and from 50%-5% to 5% for G>C and G>T transversions. In addition, we use two different sample types to compare the limit of detection of sequence variants in codons 12 and 13 of the KRAS gene between Sanger sequencing and other methodologies including shifted termination assay (STA) detection, single-base extension (SBE), pyrosequencing (PS), high- resolution melt (HRM), and real-time PCR (qPCR).

[1]  A. Lièvre,et al.  KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.

[2]  W. Shackelford,et al.  A New Technology for Mutation Detection , 2004, Annals of the New York Academy of Sciences.

[3]  T. Frebourg,et al.  Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy , 2007, British Journal of Cancer.

[4]  Robert A. Weinberg,et al.  Ras oncogenes: split personalities , 2008, Nature Reviews Molecular Cell Biology.

[5]  P. Jares,et al.  KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program , 2008, Virchows Archiv.

[6]  A. Jimeno,et al.  KRAS mutation: comparison of testing methods and tissue sampling techniques in colon cancer. , 2010, The Journal of molecular diagnostics : JMD.

[7]  C. Borg,et al.  A multiplex SNaPshot assay as a rapid method for detecting KRAS and BRAF mutations in advanced colorectal cancers. , 2011, Journal of Molecular Diagnostics.

[8]  M. Loda,et al.  Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. , 2005, The Journal of molecular diagnostics : JMD.

[9]  Jin Li,et al.  Ice-COLD-PCR enables rapid amplification and robust enrichment for low-abundance unknown DNA mutations , 2010, Nucleic Acids Res..

[10]  Z. Ronai,et al.  K-ras mutation: early detection in molecular diagnosis and risk assessment of colorectal, pancreas, and lung cancers--a review. , 2000, Cancer detection and prevention.

[11]  G. Qiao,et al.  KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib , 2008 .

[12]  Kathleen M Murphy,et al.  Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. , 2010, The Journal of molecular diagnostics : JMD.

[13]  Daniel J. Freeman,et al.  A comparability study of 5 commercial KRAS tests , 2010, Diagnostic pathology.

[14]  F. Cianchi,et al.  High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. , 2008, American journal of clinical pathology.

[15]  F.A.M. Bordonaba,et al.  Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer , 2009 .

[16]  R. Berbeco,et al.  Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing , 2008, Nature Medicine.